Insud Pharma, a pharmaceutical solutions providing company, agreed to merge with Agile Therapeutics, a women's healthcare company in a $45m deal. “We started Agile with the goal of improving women’s health through innovative, clinically differentiated products for women. We are proud of what we have been able to accomplish with our small, dedicated team: gaining approval of Twirla, the only low dose combined hormonal contraceptive patch, and developing a targeted commercial platform that allowed us to accelerate the growth of Twirla while reducing and managing our operating expenses. Now, we are excited about the future of Twirla in the hands of Exeltis, Insud’s US subsidiary, which we believe has the organization and resources to build on the growth momentum we have created. We believe this is the right path for Agile, provides a substantial premium to our current stock price, and a good development for women’s health,” Al Altomari, Agile Chairperson and CEO.